Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment
| Current Price | ₹430.60 |
|---|---|
| Market Cap | ₹2,637 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > 0 |
| P/E Ratio | -489.3 |
| Return on Equity | -0.86% |
| 52-Week Range | ₹292.40 – ₹577.65 |
| Beta (1Y) | 0.69 |
| Dividend Yield | 0.00% |
Panacea Biotec Ltd. is trading at ₹430.60, with a market capitalisation of ₹2,637 Cr.
Panacea Biotec Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > 0).
Panacea Biotec Ltd. has a P/E of -489.3 and a return on equity of -0.86%.